Spherix Global Insights

Articles by Spherix Global Insights

Tremfya’s Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights

January 14th 2025

Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation.

Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs

BySpherix Global Insights

January 14th 2025

US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights.

Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission

BySpherix Global Insights

January 14th 2025

Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for Fabhalta or Empaveli, if approved.

Spherix Global Insights

Articles by Spherix Global Insights

Tremfya’s Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights

Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs

Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission

Latest Updated Articles

Trending on HCPLive

Treatment Selection, Adherence, and Misconceptions in Pediatric Atopic Dermatitis

New Topicals in Atopic Dermatitis: Evidence, Barriers, and Real-World Perspectives

Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD

Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial

Phase 2 Data Show Early Liver Benefits With Zabopegdutide in MASH